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Abstract: Anesthesia is defined as a total or partial loss of sensation and it may be general, local or topical, depending on 
the method of drug administration and area of the body affected. General anesthesia is a reversible state of unconscious-
ness produced by anesthetic agents, characterized by amnesia, muscle relaxation and loss of sensitivity to pain of the 
whole body. General anesthetic drugs can be classified into two main groups according to their predominant molecular 
pharmacological effects: volatile and intravenous agents. Local anesthesia produce a reversible loss of sensation in a por-
tion of the body and it reversibly block impulse conduction along nerve axons and other excitable membrane. All local 
anesthetics (LA) are membrane stabilizing drugs; they reversibly decrease the rate of depolarization and repolarization of 
excitable membranes. They act mainly by inhibiting sodium influx through sodium-specific ion channels in the neuronal 
cell membrane, in particular the voltage-gated sodium channels. When the influx of sodium is interrupted, an action po-
tential cannot arise and signal conduction is inhibited. The main local anesthetic (LA) agents for skin anesthesia are ben-
zocaine (aminoester), prilocaine and lidocaine (aminoamides) which are commercially available as gels, ointments and 
creams (benzocaine and eutectic mixture of lidocaine and prilocaine) or as a bioadhesive (lidocaine) with different com-
positions (vehicles and excipients) for adults or pediatric use. Topical anesthetics decrease anxiety, pain and discomfort 
during cutaneous procedures and provide effective analgesia with rapid onset, prolonged duration and minimal side ef-
fects. This article outlines the different classes of topical anesthetics available and gives an overview of the mechanism of 
action, metabolism of each different class, of the possible complications that can occur because of their use and their pos-
sible treatment options and new patents. 
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INTRODUCTION 
 Anesthesia is defined as a loss of sensation and it may be 
general, local or topical, depending on the method of drug 
administration and area of the body affected [1]. The devel-
opment of safe and effective local anesthetic agents has pos-
sibly been one of the most important advancements in medi-
cine to occur in the last century. 
General Anesthetics 
 General anesthesia is a reversible state of unconscious-
ness produced by anesthetic agents, characterized by amne-
sia, muscle relaxation and loss of sensitivity to pain of the 
whole body. General anesthetic drugs can be classified into 
two main groups according to their predominant molecular 
pharmacological effects: volatile and intravenous agents.  
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Volatile anesthetics were first introduced into clinical use in 
1842 and can be divided into organic and inorganic agents. 
The commonly used volatile anesthetics in current clinical 
practice include isoflurane, halothane, desflurane and 
sevoflurane. They bind to many body proteins modifying 
their functions and producing an anesthetic action. Several 
protein targets have been identified for these agents such as 
ion channels, muscarinic acetylcholine receptors, opioid re-
ceptors, alpha2 adrenergic receptors, 5-hydroxytryptophan 
receptors and N-methyl-D-aspartate (NMDA) receptors [1]. 
Volatile agents provide all components of general anesthesia 
but they also have additional properties. Many animal studies 
have shown that these drugs are able to reduce inflammatory 
processes induced by various stimuli, including ischemia and 
inflammation inducing agents. Similar findings have been 
revealed in humans. Data of literature have reported, in fact, 
that sevoflurane 2% inhibits the function of inflammatory 
cells by decreasing the expression of TNFa and other cytoki-
nes such as IL-6 and IL-8 [2]. Nevertheless, current evidence 
shows dual effects of volatile anesthetics on inflammatory 
process: they can inhibit inflammation induced by several 
potentially harmful stimuli (e.g., surgery) and induce neu-
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roinflammation in the absence of stimuli. Little is known for 
the mechanisms of volatile anesthetics-induced neuroin-
flammation. Isoflurane has been shown to open the blood 
brain barrier. This can increase the permeation of intravascu-
lar substances to brain tissues. Furthermore, isoflurane seems 
to activate NF-kB, a transcription factor known to increase 
inflammatory cytokine production, causing neuroinflamma-
tion that then leads to cognitive impairment [3]. As regards 
their side effects, in literature are reported the following: 
increased intracranial pressure, hypotension, cardiac ar-
rhythmias, airway irritability and depression of mucociliary 
system [1]. 
 Intravenous anesthetics were introduced into clinical use 
for the first time in 1939 [1]; they can be divided into barbitu-
rates and non-barbiturates agents. Barbiturates are a class of 
drugs that act on the GABAA receptor in the brain and spinal 
cord. The GABAA receptor is an inhibitory channel that de-
creases neuronal activity, and barbiturates enhance the inhibi-
tory action of the GABAA receptor. Barbiturates have 
anesthetic, sedative, anxiolytic, anticonvulsant and hypnotic 
properties but do not have analgesic effects. The main repre-
sentative agent of this class is thiopentone. As with nearly all 
anesthetic drugs, thiopentone causes cardiovascular and respi-
ratory depression resulting in hypotension, apnea and airway 
obstruction. Side effects also include headache, agitated emer-
gence, prolonged somnolence, and nausea [1]. Among the 
non-barbiturates anesthetics, the most commonly used are 
propofol and ketamine. Propofol has been proposed to have 
several mechanisms of action both through potentiation of 
GABAA receptor activity, thereby slowing the channel-closing 
time, and also acting as a sodium channel blocker [1]. Recent 
research has also suggested that the endocannabinoid system 
may contribute significantly to propofol's anesthetic action and 
to its unique properties [4]. Aside from low blood pressure 
related to vasodilation, and transient apnea following induc-
tion doses, one of propofol's most frequent side effects is pain 
on injection, especially in smaller veins. This pain arises from 
activation of the pain receptor, TRPA1, found on sensory 
nerves, and it can be mitigated by pretreatment with lidocaine 
[5]. Other rare side effects are dystonia and priapism. Keta-
mine is classified as an NMDA receptor antagonist, but it also 
interacts with muscarinic receptors, descending monoaminer-
gic pain pathways and voltage-gated calcium channels [1]. In 
literature short term and long term side effects are reported. 
The first ones occur immediately after the operation and they 
are transitory: delirium, dizziness, diplopia, blurred vision, 
nystagmus, tachycardia, hypersalivation, nausea and vomiting, 
erythema, aphasia, psychomotor retardation, nightmares, hal-
lucinations and tonic-clonic movements. Long term side ef-
fects arise a few months after the anesthesia and they mainly 
comprise neurological effects (cognitive impairments, depres-
sion memory problems) and urinary tract effects (inconti-
nence, decreased bladder compliance, detrusor overactivity, 
painful haematuria, bilateral hydronephrosis and renal papil-
lary necrosis) [6]. Inhalational and intravenous anesthetics 
may both cause and mitigate existing significant neuropathol-
ogy and they may cause neuroapoptosis, caspase activation, 
neurodegeneration, ?-amyloid protein (A?) accumulation and 
oligomerization, and ultimately, deficits in neurocognition [7]. 
Local Anesthetics 
 Local anesthesia produces a reversible loss of sensation 
in a portion of the body and it reversibly blocks impulse 
conduction along nerve axons and other excitable mem-
branes. Local anesthetics (LA) interrupt neural conduction 
by inhibiting the influx of sodium ions through channels or 
ionophores within neuronal membranes. When the influx of 
sodium is stopped, an action potential cannot arise and signal 
conduction is inhibited. The use of LA dates back to the sec-
ond half of the nineteenth century. These drugs vary in their 
pharmacological properties and they are used in various 
techniques of local anesthesia such as: topical anesthesia 
(surface), infiltration, plexus block, epidural (extradural) 
block and spinal anesthesia (subarachnoid block). LA can be 
classified as ester- or amide-derived local anesthetics. Their 
basic structure consists of an aromatic lipophilic ring and an 
amine hydrophilic group connected by an intermediate hy-
drocarbon chain. Ester and amide anesthetics differ in their 
chemical stability and metabolism. The amino esters are rela-
tively unstable in solution and are easily hydrolyzed in the 
body by plasma cholinesterase and other nonspecific es-
terases. One metabolite formed by this ester hydrolysis reac-
tion is para-aminobenzoic acid (PABA), which is capable of 
causing allergic reactions in a small percentage of patients. 
In contrast, the amino amides are much more stable and un-
dergo enzymatic degradation in the liver. Because they are 
not metabolized to PABA, allergic reactions to the amide-
type local anesthetics are extremely rare [1]. The amino am-
ides include lidocaine, mepivacaine, prilocaine, bupivacaine, 
etidocaine, ropivacaine; the amino esters comprehend co-
caine, procaine, clorprocaine, tetracaine and benzocaine. 
Systemic toxicity includes side effects on the central nervous 
system and the heart. As local anesthetics are absorbed from 
the injection site, their concentration in the bloodstream rises 
and the peripheral nervous system (PNS) and central nervous 
system (CNS) are depressed in a dose-dependent manner. 
Although all local anesthetics carry comparable risk for CNS 
toxicity, it should be noted that bupivacaine exhibits greater 
potential for direct cardiac toxicity than other agents [8]. 
Even levobupivacaine and ropivacaine (single-enantiomer 
derivatives) developed to ameliorate cardiovascular side ef-
fects, still harbor the potential to disrupt cardiac function [9]. 
The systemic toxicity of prilocaine is comparatively low, 
however its metabolite, O-toluidine, is known to cause 
methemoglobinemia. As methemoglobinemia reduces the 
amount of hemoglobin that is available for oxygen transport, 
this side effect is potentially life-threatening. Therefore, dose 
limits for prilocaine should be strictly observed [10]. Local 
anesthetics may also cause allergic reactions. In literature are 
reported either a syncopal episode associated with the injec-
tion, or cardiac palpitations attributed to epinephrine con-
tained either in the solution or released endogenously. Aller-
gic reactions following local anesthetic injections are more 
likely attributable to preservatives (methylparaben) or anti-
oxidants (sulfites) contained in the solution [11]. Local anes-
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thetics could also induce histological damage with lesions 
ranging from local to extreme in skeletal muscle. Metabolic 
alterations were also described involving sarcoplasmic re-
ticulum and calcium dysregulation, alteration of mitochon-
drial physiology and of oxidative phosphorylation with asso-
ciated overproduction of harmful reactive oxygen species, 
causing apoptosis or necrosis [12]. 
Topical Anesthetics 
 Topical anesthesia is one of the most used strategies to 
minimize anxiety, pain and discomfort at the site of the nee-
dle insertion during dermatological surgical procedures. The 
main topical anesthetic agents for skin anesthesia are benzo-
caine (aminoester), prilocaine and lidocaine (aminoamides) 
which are commercially available as gels, ointments and 
creams (benzocaine and eutectic mixture of lidocaine and 
prilocaine) or as a bioadhesive (lidocaine) with different 
compositions (vehicles and excipients) for adults or pediatric 
use. The purpose of such topical formulations is to promote 
the permeation at site of application and a rapid onset of ac-
tion, enhancing the topical anesthetic effect and reducing the 
pain associated with dermatological procedures. The first 
topical anesthetic mixture reported was composed 0.5% tet-
racaine, 0.05% epinephrine and 11.8% cocaine. The high 
local and systemic toxicity limited its use, and a mixture of 
4% lidocaine, 0.5% tetracaine and 0.1% epinephrine was 
proposed for replacing cocaine. In 1992, the eutectic mixture 
of 2.5% lidocaine and 2.5% of prilocaine known as EMLA 
was approved by the US FDA, being the main anesthetic 
formulations for skin anesthesia due to its efficacy and safety 
for a variety of procedures in dermatology. Topical anesthet-
ics efficacy has been evaluated by different methods such as 
pinprick and tail flick tests in pre-clinical studies. At the 
same way, tactile spatial discrimination, puncture of intact 
skin and tape-stripping technique have been used for clinical 
efficacy evaluation. Topical formulations containing LA are 
usually applied on the skin for analgesia or for the manage-
ment of acute and chronic superficial pain. Most of the for-
mulations available are liquid or semisolids. The main draw-
back of these formulations is that they can be easily removed 
from the skin surface by rubbing of clothing or inadvertent 
touching, reducing the contact time with the skin and conse-
quently modifying the efficacy. A relatively new alternative 
formulation is represented by patches that normally consist 
of an outer covering which support a preparation that con-
tains the active substance intended to be applied to intact 
skin to obtain a local and systemic delivery. Unlike the tradi-
tional topical formulations, the patches guarantee the control 
of the applied dose, of the area of application, of the contact 
time and of the release kinetics. The first patch containing 
topical anesthetics, namely lidocaine, was approved by FDA 
in 1999 for the treatment of postherpetic neuralgia. The lido-
caine patch 5% consists of a thick layer of adhesive hydrogel 
containing the active applied on a woven-non woven backing 
and covered by a polyethylene terephthalate release liner. 
Lidocaine patch is nowadays a first-line treatment of 
postherpetic neuralgia or other localized pain conditions and 
its efficacy was demonstrated by many studies. The devel-
opment of topical anesthetic formulations and its widespread 
use has become an alternative to reduce pain and anxiety 
related to invasive procedures, such as venipuncture, pin-
prick testing, and split-thickness skin graft donation. Com-
bined anesthetic agents have been widely used in the clinical 
practice for skin anesthesia. The combination between topi-
cal anesthetics agents and/or vasoconstrictors was the first 
strategy for skin anesthesia. Nowadays, in order to provide a 
fast onset and to prolong the duration of anesthesia, some of 
the different strategies purposed include liposomes, lipid 
nanoparticles, formulations of hydrogels and also highly 
water permeable patches have been reported in a variety of 
studies, pulled together here. Liposomes are microscopic, 
spherical, phospholipid-based carriers that deliver a greater 
concentration of local anesthetic to sensory nerves than other 
conventional formulations with lower lipophilicity [13]. 
However, despite the availability of different procedures and 
formulations, the development of an ideal topical anesthetic 
formulation for skin-delivery is still a challenge. The main 
limitation is the stratum corneum barrier due to its lipid 
phase composition and organization. Several techniques can 
improve dermal absorption of topical anesthetics. Removing 
the stratum corneum with preoperative procedures such as 
tape stripping, degreasing with acetone or laser ablation en-
hances dermal absorption. Occlusion and heat can also facili-
tate anesthetic penetration into the skin. Iontophoresis in-
creases absorption of topical anesthesia by using an electric 
current to facilitate the passage of ionized local anesthetic 
into and across the skin barrier. Adding epinephrine to local 
anesthetic induces vasoconstriction, which slows the anes-
thetic’s removal and raises the duration of its local tissue 
effect [14]. Toxic reactions to topically applied anesthetics 
correlate with their peak blood levels. Peak blood levels are 
achieved more quickly with topical anesthetics applied to 
mucous membranes and large areas of skin. If a large area of 
skin is involved, treatments should be divided into smaller 
anatomic portions so that appropriately sized segments of 
skin are anesthetized and treated during each session. Im-
proper applications of topical anesthetic formulations such as 
benzocaine, lidocaine, and tetracaine may cause serious 
complications, including cardiotoxicity and central nervous 
system toxicity [15]. 
SKIN ANESTHETICS 
Eutectic Mixture of Local Anesthetics 
 The topical anesthetic agent widely used is a eutectic 
mixture of local anesthetics (EMLA; Astra Pharmaceuticals, 
Westborough, MA). EMLA is an oil-in-water emulsion of 
2.5%, lidocaine and 2.5% prilocaine wich contains 
polyoxyethylene fatty acid esters functioning as emulsifier, 
which enhance the skin penetration by increasing the effec-
tive concentration of anesthetics in the oil droplet to 80%. 
EMLA is often applied to the skin under an occlusive dress-
ing, which facilitates absorption; it has a recommended 1-
hour minimal application time on intact skin, although the 
onset of cutaneous analgesia depends on the anatomic site. 
For example, EMLA is ineffective on palmar and plantar 
areas, while, for the mucous membranes (genitalia, lips), 
effective anesthesia can usually be obtained within 5 to 15 
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minutes without occlusion. The depth of the analgesia is 
highly correlated with the duration of application. For par-
ticular painful procedures, such as skin graft harvesting, the 
recommended time is at least 2 hours. Dermal analgesia 
reaches maximum at 2 to 3 hours after application and per-
sists 1 to 2 hours after removal [16]. EMLA has a biphasic 
action on cutaneous blood vessels, with a vasoconstrictive 
effect that is maximal after 1.5 hours, followed by vasodila-
tation 2 to 3 hours after application. EMLA works by abol-
ishing pain and decreasing the itch sensation and it is able to 
relieve the pain associated with venopuncture and venous 
cannulation, biopsies, curettage of molluscum contagiosum, 
split-thickness skin grafts, and debridement of chronic leg 
ulcers, chemical peels, epilation, and vascular laser treat-
ments. The maximum recommended dose and application 
area are based on patient’s age, body weight, intact skin, and 
normal renal and hepatic function. The concentrations asso-
ciated with systemic toxicity are in the region of 6?g/mL. 
The major concern regarding the use of EMLA relates to the 
potential risk of methemoglobinemia. It seems that the risk 
of developing this side effect is mainly due to the prilocaine 
portion of EMLA because of its ability to oxidize iron in red 
blood cells from the ferrous to the ferric state, compromising 
hemoglobin transport of oxygen. When levels of methemo-
globin are between 15% and 30%, patients present with ini-
tial signes of cyanosis, including dyspnea, tachycardia, and 
headache. Methemoglobin levels greater than 50% are asso-
ciated with lethargy and coma [17]. Hypersensitivity reac-
tions and systemic toxicity from EMLA are extremely rare. 
The use of EMLA is contraindicated in patients with a 
known history of sensitivity to amide-type local anesthetics. 
Because it is metabolized in the liver, patients with liver dis-
ease should consider it a relative contraindication. Patients 
with skin disease such as atopic dermatitis and psoriasis may 
have higher rates of absorption and side effects. EMLA is 
safe to administer on intact skin of full-term neonates, but 
care must be taken to limit the dose and area of application. 
Oral ingestion may lead to toxicity because of rapid systemic 
uptake via the mucous membrane. Minor application-site 
side effects include paleness, redness, and alteration in tem-
perature sensations, edema, itching, and rash. Local reactions 
can be exacerbated by repeated applications but usually re-
solve after discontinuation. Eye contact with EMLA should 
be avoided because it contains sodium hydroxide that may 
cause alkaline chemical injury [18]. 
ELA-Max 
 ELA-Max (Ferndale Laboratories, Ferndale, Mich) is a 
topical anesthetic cream with 4% lidocaine at pH 7.4. Each 
gram of ELA-Max cream contains lidocaine (40 mg), vita-
min E acetate, propylene glycol, benzyl alcohol, lecithin, 
cholesterol, carbomer 940, triethanolamine, polysorbate 80, 
and purified water. It is used for the temporary relief of pain 
associated with minor cuts and abrasions of the skin, minor 
burns, and skin irritation. It is not recommended for mucous 
membrane use because limited studies have shown greater 
absorption of lidocaine than through intact skin.  
 The onset, depth, and duration of cutaneous analgesia 
depend primarily upon the duration of application, and the 
amount of lidocaine systemically absorbed is directly related 
to these variables. 
 The incidence of adverse reactions is limited. Topical 
adverse reactions consist of irritation and erythema, so eye 
contact with ELA-Max should be avoided. The low rate of 
systemic side effects is due to low peak blood levels. Toxic 
levels occur at more than 5?g/mL for lidocaine and cause 
decreases in cardiac output, total peripheral resistance, and 
mean arterial pressure. Overdose symptoms may include also 
seizures, respiratory failure, and coma [19]. 
Lidocaine 
 Lidocaine, alone or in combination with another anes-
thetic, is the most widely used topical anesthetic. It belongs 
to the amide class of anesthetics, which has less risk of in-
ducing an allergic reaction than ester anesthetics. Brand 
names for OTC topical lidocaine include Topicaine (ESBA 
Laboratories, Jupiter, FL), Lidoderm (Endo Pharmaceuticals, 
Chadds Ford, PA), and LMX (Ferndale Laboratories, 
Ferndale, MI). Topicaine is a 4% or 5% lidocaine gel, and 
Lidoderm is a 5% lidocaine adhesive patch. LMX is a 4% or 
5% lidocaine liposomal delivery cream that has several lipid 
bilayers, which facilitate dermal penetration of anesthetic 
and protect the drug from being rapidly metabolized, allow-
ing LMX to achieve the same analgesia as EMLA in a 
shorter period of time without requiring occlusion [20]. 
 Lidocaine is excreted through breast milk, so caution 
should be practiced when being administered to a nursing 
mother. Topical adverse effects can occur and they mainly 
appear as erythema, irritation and itching. Care must be ex-
ercised with use of topical lidocaine around the eye because 
accidental eye exposure will result in severe corneal irrita-
tion. 
 Prolonged applications, use of inappropriately high 
concentrations, and distribution to large surface areas in-
crease the risk of cardiotoxicity and central nervous system 
toxicity. The initial symptoms of lidocaine-induced toxicity 
(for blood levels of 1-5?g/mL) include lightheadedness, 
circumoral numbness, diplopia, and tinnitus. When levels 
of lidocaine are between 20 and 25?g/mL, patients present 
with respiratory depression or coma. Many adverse reac-
tions also appear to be related to the inclusion of epineph-
rine within the anesthetic mixture [21]. Several prepara-
tions of topical lidocaine are available for anesthesia of oral 
mucous membranes: 2% viscous solution, 5% liquid and 
5% ointment (Xylocaine, Astra Inc, Westborough, Mass). 
These topical agents are recommended for the prevention 
and treatment of oral mucosa pain, especially in children. 
The main indications are symptomatic treatment of minor 
injuries (such as trauma or aphtous ulcers) of oropharynx 
membranes or prevention of iatrogenic pain produced dur-
ing painful dental procedures such as anesthetic injection or 
clamp placement [22]. 
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S-Caine Peel and S-Caine  
 Patch An S-Caine peel, marketed as Pliaglis (Galderma 
Laboratories, Fort Worth, TX), was a eutectic mixture of 7% 
lidocaine and 7% tetracaine in a cream base. It was discon-
tinued in September 2008 because of an inability to obtain 
consistent product viscosity. 
 Plans for its re-release are unclear. The S-Caine Patch 
(Zars, Inc., Salt Lake City, UT) contains a small amount of 
topical anesthetic under a patented heating element that 
raises the temperature to 40°C for longer than 14 hours and 
enhances delivery of the anesthetic. This product is marketed 
as Synera and contains a eutectic mixture of 70mg of lido-
caine and 70mg of tetracaine. When the patch is applied to 
the skin, it increases the skin temperature approximately 
5°C, but the maximum skin temperature produced by the 
patch at the site of application does not exceed 40°C [23]. 
The product manufacturer states that the patch should be 
placed on intact skin 30 minutes before superficial derma-
tologic procedures such as a shave biopsy. Erythema, 
blanching, and edema are the most commonly observed local 
reactions. 
MUCOUS MEMBRANE AND OPHTHALMIC ANES-
THETICS 
 Among topical anesthetics, it is worth mentioning the mu-
cous membrane and the ophthalmic anesthetics. Mucous 
membrane anesthetics include Benzocaine and Cocaine. The 
first one exists in liquid, gel and spray formulations for oral 
anesthesia. It is used for treatment of minor mouth or gum 
wounds and inflammation. It is an ester local anesthetic; hence 
there is a small risk of the development of contact allergy. 
Adverse systemic reactions are uncommon but it can poten-
tially induce methemoglobinemia [24]. Cocaine is the active 
alkaloid derived from the leaves of the Erythroxylon coca 
plant of South America. It lessens the sensibility to pain and 
diminishes the acuity of taste and smell. Topical cocaine pro-
duces anesthesia by preventing nerve impulse conduction and 
causes intense vasoconstriction by blocking the presynaptic 
reuptake of norepinephrine. Maximum local anesthesia occurs 
within 5 minutes and persists for up 60 minutes. Cocaine is 
highly effective on mucous membranes, but it is no well ab-
sorbed through intact skin; it is commonly used for topical 
anesthesia of the oral and nasal cavities and larynx [25]. 
 Allergic reactions are uncommon. More frequent is the 
necrosis of nasal septum in patients who abuse cocaine. As 
regard systemic effects, cocaine may induce euphoria and 
increased alertness. Its sympathomimetic effects include 
hypertension, hyperthermia and tachycardia. Cocaine over-
dose (200 mg) can lead to convulsion, CNS depression respi-
ratory failure and death. 
Ophthalmic Anesthetics Include Proparacaine and Tet-
racaine 
 Proparacaine’s dermatologic indications are for removal 
of superficial foreign bodies from the cornea and short op-
erative procedures involving the eyelid. Proparacaine is a 
rapidly acting acid ester anesthetic. The usual dose is 1 or 2 
drops of 0.5% solution before the procedure; the onset of 
anesthesia usually begins in 30 seconds and persists for 
about 15 minutes. At usual dosages, proparacaine produces 
minimal local side effects. However, with prolonged use, it 
may retard wound healing and cause corneal epithelial ero-
sions [26]. In literature are also described few cases of aller-
gic contact dermatitis [27]. Systemic effects from procaine 
are rare; however toxicity may occurs with the stimulation of 
CNS, followed by CNS and cardiovascular depression. Tet-
racaine is employed in a 0.5% solution for topical use. It is a 
para-aminobenzoic acid ester whose mechanism of action is 
similar to that of propacain. The main side effect of tetra-
caine is the burning sensation encountered during the 30 
seconds after instillation into the conjunctival sac. Local 
toxicity to tetracaine may occur after repeated use. Danger-
ous overdosage (higher than 1.5 mg/Kg of the body weight) 
can produce side effects similar to those of proparacaine 
[28]. 
CURRENT & FUTURE DEVELOPMENTS  
 Thanks to the more widely use of these agents’ new pat-
ents are developing in recent years; we will review them. An 
interesting discovering was treating neutrophil-associated 
pulmonary disease administering a topical anesthetic e.g. 
lidocaine, locally to the respiratory tract. A therapeutic 
method is provided to treat neutrophil-associated pulmonary 
diseases, such as chronic obstructive pulmonary disease, by 
locally administering an effective amount of a topical anes-
thetic, such as lidocaine, to counteract the symptoms of the 
disease [29].  
 Another invention useful for ameliorating neurogenic 
tremor e.g., kinetic, postural, task specific or resting, in 
mammals, comprises topically administering anesthetic [30].  
 A method for providing applicator of e.g., topical anes-
thetic for dental patient, involves attaching absorbent mate-
rial at end of cap, such that medicinal substance is applied to 
material, and end of cap with material is applied to body 
[31]. 
 Another new invention included transdermal analgesic 
applicator configured to provide a visual signal subsequent 
sufficient absorption of an analgesic compound ensuing the 
transdermal analgesic applicator being applied to the skin of 
a patient. The transdermal analgesic applicator includes a 
first layer that is impermeable and has integrally formed 
therewith on at least a portion thereof a plurality of micro-
capsules containing a thermochromic dye mixture. The first 
layer having the portion of microcapsules presents a first 
color at ambient room temperature and a second color at 
temperature greater than the first temperature as a result of 
being placed on the skin of a patient. A second layer contain-
ing an analgesic compound is secured to the first layer. The 
first layer changes from the first color to the second color 
subsequent the first layer changing from the first temperature 
to the second temperature, which the rate of temperature 
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change is approximately equivalent to the absorption rate of 
the analgesic compound [32].  
 The various embodiments of the present inventions pro-
vide stabilization devices and methods for use of the stabili-
zation devices with minimally invasive gynecological proce-
dures such as methods of preventing pregnancy by inserting 
intrafallopian contraceptive devices into the fallopian tubes 
full of topical anesthetics. A minimally invasive method of 
sterilization, the method comprising: coupling a handle of an 
elongated catheter to an endoscope, the endoscope having a 
handle and an elongated portion designed for insertion into a 
patient, and the elongated catheter having an outer portion, 
an inner portion within the outer portion, and a corewire 
within the inner portion, wherein the outer portion and inner 
portion are slideable relative each other; inserting the elon-
gated catheter and the endoscope into a uterus of the patient; 
inserting a sterilization device coupled to a distal portion of 
the elongated catheter into a fallopian tube of the patient, the 
sterilization device having an outer expandable portion; 
moving a release mechanism on the handle from a first in-
cremented position having a first labeled operation to a sec-
ond incremented position having a second labeled operation, 
the first and second labeled operations each referring to an 
operation in removing the sterilization device from the elon-
gated catheter; and wherein moving the release mechanism 
from the first incremented position to the second incre-
mented position causes: activating the outer expandable por-
tion of the sterilization device to expand inside the fallopian 
tube; and withdrawing the corewire from the expanded ster-
ilization device to fully disengage the expanded sterilization 
device from the elongated catheter while keeping the endo-
scope and elongated catheter in a stable position rotationally 
relative to the patient [33, 34].  
 A composition comprising an antacid, and a local, topical 
anesthetic is used to relieve pain or discomfort associated 
with a sore throat (viral or bacterial infection, or a common 
or seasonal allergy), and therefore, the invention is also di-
rected to a method of alleviating the pain or discomfort asso-
ciated with a sore throat comprising instructing a human to 
orally administer the composition. The composition provides 
a controlled antacid delivery form for the administration of 
an antacid [35]. 
 A method of topically applying an anesthetic or other 
medication, to one or both lips of the mouth is discussed by 
Jones. An applicator device is provided that has a curved 
first wall, a curved second wall, and a horizontal shelf that 
joins the first wall to the second wall. The first wall, the sec-
ond wall and the horizontal shelf combine to define either 
one or two curved lip compartments. A volume of the anes-
thetic, or other medication, is placed within the curved lip 
compartments. The applicator device is partially placed in a 
person's mouth so that the second wall is positioned between 
the back of the lips and in front of the teeth. In this position, 
the lips of the user passes into the curved lip compartment 
and come in contacted by the anesthetic [36, 37]. 
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